IPX-461 is a thiazolidinedione, a class of drugs that work by activating peroxisome proliferator-activated receptors (PPARs), specifically PPAR-γ. Activation of PPAR-γ enhances the transcription of genes involved in glucose and lipid metabolism.
The efficacy of IPX-461 was evaluated in several studies, which showed that it: IPX-461
IPX-461 was studied in several clinical trials for the treatment of type 2 diabetes. These trials aimed to evaluate the efficacy and safety of IPX-461 as monotherapy or in combination with other antidiabetic agents. IPX-461 is a thiazolidinedione, a class of drugs
The four‑size silicone tip set ensures a secure seal for most ear shapes. In a 20‑person fit‑test: Because the buds have a slightly rounded “bezel‑free”
Because the buds have a slightly rounded “bezel‑free” shape, they sit deep enough for passive isolation, reducing the reliance on ANC in noisy environments.
The regulatory status of IPX-461 varies by country. In the United States, IPX-461 was granted orphan drug designation for the treatment of type 2 diabetes. However, the development of IPX-461 was discontinued due to concerns about its safety and efficacy.